ArticleAnnals of neurology2022
Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers.
Article in Annals of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 3 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Short-and long-term responsiveness of deep brain stimulation on motor and cognitive outcomes in GBA vs. Non-GBA parkinson's disease: a systematic review and meta-analysis of observational studies.Neurosurgical review · 2026Pooled it
- Invasive therapies for Parkinson's disease: an adapted excerpt from the guidelines of the German Society of Neurology.Journal of neurology · 2025Pooled it
- Motor and Non-motor Outcomes of Deep Brain Stimulation across the Genetic Panorama of Parkinson's Disease: A Multi-Scale Meta-Analysis.Movement disorders clinical practice · 2024Pooled it
- What's in a name? reframing advanced Parkinson's disease as a multidimensional state.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Clinical and Biological Determinants of Longitudinal Cognitive Function in Patients With GBA1 Variants and Subthalamic Deep Brain Stimulation.Annals of neurology · 2026Article
- Motor and Cognitive Outcome After Subthalamic Nucleus Deep Brain Stimulation in Patients with Parkinson's Disease Harboring GBA1 Variant.Movement disorders clinical practice · 2026Article
- Sources of Oxidative Stress in Parkinson's Disease: Pathways and Therapeutic Implications.Antioxidants (Basel, Switzerland) · 2026Review
- The interplay between GBA1 status and age of onset on cognitive, motor and non-motor outcomes in Parkinson's disease: multicenter cross-sectional study.Journal of neurology · 2026Article
- Multi-omics insights into GBA1-associated Parkinson's disease: interplay of genomics, transcriptomics, proteomics, and lipidomics.Molecular neurodegeneration · 2026Review
- Clinical Utility ofGenes · 2026Review
- Effect of deep brain stimulation on early-onset Parkinson's disease with mutations in a Han Chinese Mainland population.BMC neurology · 2026Article
- Consensus expert recommendations for referral of Parkinson's disease patients for deep brain stimulation surgery.NPJ Parkinson's disease · 2026Review
- Early-Onset Parkinson's Disease: Unique Features and Management Approaches.Current neurology and neuroscience reports · 2025Review
- How many do we miss? - Evaluation of age at onset and family history as selection criteria for genetic testing in Parkinson's disease.medRxiv : the preprint server for health sciences · 2025Article
- Long-Term Motor and Cognitive Outcome of Deep Brain Stimulation in Patients With Parkinson Disease With aNeurology · 2025Article
- Unraveling the role of GBA1 genotype in axial signs response to subthalamic deep brain stimulation.NPJ Parkinson's disease · 2025Article
- Severe GBA1 variants drive the GBA1-PD clinical phenotype: implications for counselling and clinical trials.NPJ Parkinson's disease · 2025Article
- Identifying Poor Responders to STN DBS in Parkinson Disease: The Role of Rapid Disease Progression in the First Year in Optimal Responders to Levodopa.European journal of neurology · 2025Article
- Deep brain stimulation surgical timing, outcomes, and prognostic factors in patients with Parkinson's disease: A Chinese retrospective multicenter cohort study.PLoS medicine · 2025Article
- Barriers to clinical genetic testing in movement disorders.Current opinion in neurology · 2025Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
31 authors at 12 institutions in 5 countries.
Funding
Abstract
objectiveThis study was undertaken to compare the rate of change in cognition between glucocerebrosidase (GBA) mutation carriers and noncarriers with and without subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson disease.
methodsClinical and genetic data from 12 datasets were examined. Global cognition was assessed using the Mattis Dementia Rating Scale (MDRS). Subjects were examined for mutations in GBA and categorized as GBA carriers with or without DBS (GBA+DBS+, GBA+DBS-), and noncarriers with or without DBS (GBA-DBS+, GBA-DBS-). GBA mutation carriers were subcategorized according to mutation severity (risk variant, mild, severe). Linear mixed modeling was used to compare rate of change in MDRS scores over time among the groups according to GBA and DBS status and then according to GBA severity and DBS status.
resultsData were available for 366 subjects (58 GBA+DBS+, 82 GBA+DBS-, 98 GBA-DBS+, and 128 GBA-DBS- subjects), who were longitudinally followed (range = 36-60 months after surgery). Using the MDRS, GBA+DBS+ subjects declined on average 2.02 points/yr more than GBA-DBS- subjects (95% confidence interval [CI] = -2.35 to -1.69), 1.71 points/yr more than GBA+DBS- subjects (95% CI = -2.14 to -1.28), and 1.49 points/yr more than GBA-DBS+ subjects (95% CI = -1.80 to -1.18).
interpretationAlthough not randomized, this composite analysis suggests that the combined effects of GBA mutations and STN-DBS negatively impact cognition. We advise that DBS candidates be screened for GBA mutations as part of the presurgical decision-making process. We advise that GBA mutation carriers be counseled regarding potential risks associated with STN-DBS so that alternative options may be considered. ANN NEUROL 2022;91:424-435.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.